{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genes&page=2", "query": { "condition": "Genes", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genes&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T20:25:36.878Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03374202", "title": "Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infected Adults With Controlled Viremia" ], "interventions": [ { "name": "VRC-HIVAAV070-00-GT (AAV8-VRC07)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2018-01-11", "completion_date": "2026-08-08", "has_results": true, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374202" }, { "nct_id": "NCT00647439", "title": "Genetics and Markers of Degenerative and Inflammatory Eye Diseases", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Retinopathy", "Age-Related Macular Degeneration (AMD)", "Uveitis" ], "interventions": [], "intervention_types": [], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 609, "start_date": "2008-03-27", "completion_date": "2018-12-04", "has_results": false, "last_update_posted_date": "2018-12-10", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00647439" }, { "nct_id": "NCT04903119", "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "BRAF Gene Mutation" ], "interventions": [ { "name": "Nilotinib 100mg", "type": "DRUG" }, { "name": "Nilotinib 200mg", "type": "DRUG" }, { "name": "Nilotinib 300mg", "type": "DRUG" }, { "name": "Nilotinib 400mg", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rina Plattner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-06-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Easton", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903119" }, { "nct_id": "NCT00918008", "title": "A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Blood draw", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 12, "start_date": "2009-06", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00918008" }, { "nct_id": "NCT00087789", "title": "CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "CERE-110: Adeno-Associated Virus Delivery of NGF", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Sangamo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 10, "start_date": "2004-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2022-11-10", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 2, "location_summary": "San Diego, California • Chicago, Illinois", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087789" }, { "nct_id": "NCT01727531", "title": "IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Metastasis" ], "interventions": [ { "name": "Chloroquine diphosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Main Line Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2008-12", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2015-04-08", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 1, "location_summary": "Wynnewood, Pennsylvania", "locations": [ { "city": "Wynnewood", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727531" }, { "nct_id": "NCT06995677", "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low-grade NMIBC", "FGFR Gene Amplification", "FGFR Gene Alterations", "FGFR3 Gene Alteration", "FGFR3 Gene Mutation", "FGFR3 Gene Fusions" ], "interventions": [ { "name": "TYRA-300 60mg", "type": "DRUG" }, { "name": "TYRA-300 50mg", "type": "DRUG" }, { "name": "TYRA-300 Dose TBD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-06-27", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 28, "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995677" }, { "nct_id": "NCT03428802", "title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Locally Advanced Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "POLD1 Gene Mutation", "POLE Gene Mutation", "Recurrent Malignant Solid Neoplasm", "Recurrent Ovarian Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v8", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-03-08", "completion_date": "2027-09-21", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • New York, New York", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428802" }, { "nct_id": "NCT00497705", "title": "Genes Causing Ebstein's Anomaly", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Septal Defects, Ventricle", "Heart Defects, Congenital", "Double Outlet Right Ventricle", "Truncus Arteriosus, Persistent" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "2007-07-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00497705" }, { "nct_id": "NCT02710500", "title": "rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dysferlinopathy" ], "interventions": [ { "name": "rAAVrh74.MHCK7.DYSF.DV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-03", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-06-07T20:25:36.878Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02710500" } ] }